Capital Group Private Client Services Inc. Decreases Holdings in AbbVie Inc. $ABBV

Capital Group Private Client Services Inc. lowered its holdings in AbbVie Inc. (NYSE:ABBV) by 79.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 55,095 shares of the company’s stock after selling 209,169 shares during the quarter. Capital Group Private Client Services Inc.’s holdings in AbbVie were worth $12,757,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie during the 2nd quarter worth approximately $26,000. Caitlin John LLC acquired a new stake in AbbVie during the 3rd quarter worth $33,000. Financial Gravity Companies Inc. acquired a new position in AbbVie in the second quarter valued at $36,000. Delos Wealth Advisors LLC acquired a new position in AbbVie in the second quarter valued at $39,000. Finally, Redmont Wealth Advisors LLC purchased a new position in shares of AbbVie during the third quarter worth about $41,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ABBV shares. Berenberg Bank set a $275.00 target price on AbbVie in a report on Tuesday, January 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. The Goldman Sachs Group restated a “neutral” rating and set a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $253.15.

Insider Buying and Selling

In other news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.08% of the company’s stock.

AbbVie Price Performance

ABBV stock opened at $227.75 on Tuesday. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The stock has a market cap of $402.70 billion, a price-to-earnings ratio of 96.50, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The company has a fifty day moving average price of $224.66 and a two-hundred day moving average price of $224.33.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the company posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is 293.22%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase 1 ABBV‑295 (long‑acting amylin analog) showed clinically meaningful weight loss (~7.8–9.8% at week 12/13) with favorable tolerability, supporting continued development as a non‑incretin obesity option. AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
• Positive Sentiment: Positive Phase 3 AFFIRM topline results for risankizumab (SKYRIZI) in Crohn’s disease point to label expansion and incremental sales upside for an already commercialized franchise. AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease
• Positive Sentiment: Analyst support: J.P. Morgan reiterated a Buy rating, which reinforces investor confidence in AbbVie’s mix of cash flow, dividend, and pipeline optionality. J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
• Positive Sentiment: Industry coverage notes ABBV‑295’s competitive profile vs. GLP‑1/GIP approaches, which could drive differentiated positioning if later‑stage data hold up. AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
• Neutral Sentiment: Analyst / media attention (Zacks, Yahoo) is elevating interest in ABBV as a momentum/dividend name, but these are background supports rather than immediate catalysts. Here’s Why AbbVie (ABBV) is a Strong Momentum Stock
• Neutral Sentiment: Broader write‑ups synthesize recent trial updates into AbbVie’s valuation/growth outlook — useful context but not a single-day catalyst. AbbVie Trial Updates Add Context To Valuation And Growth Outlook
• Negative Sentiment: Despite positive ABBV‑295 numbers, shares fell after the readout — investors may be disappointed relative to expectations versus GLP‑1/GIP therapies or are focusing on pathway uncertainty and commercialization risk. AbbVie’s Early Obesity Drug Data Shows Up To 10% Weight Loss
• Negative Sentiment: ICER will review AbbVie’s Parkinson’s drug — a health‑economics review can lead to pricing/reimbursement pressures if cost‑effectiveness is questioned. ICER to review AbbVie’s Parkinson’s disease drug
• Negative Sentiment: Corporate/financial items: an SVP sold about $1.22M of stock and AbbVie has tied roughly $350M to the amylin program — insider selling and program commitments can be read as modest near‑term negatives for sentiment or cash deployment. AbbVie (NYSE:ABBV) SVP Sells $1,221,518.80 in Stock AbbVie ties $350m amylin bet to almost 10% weight loss after 12 weeks

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.